Search
Protalix Biotherapeutics Inc
PLXAdd to Watchlist
2.480USD
-0.070-2.75%
Close 10-26 16:00（ET）
199.81MMarket Cap
12.87P/E TTM
After-hours 18:30 (ET)2.480USD-0.005-0.20%
After-hours 18:30 (ET)Today
-2.75%
5 Days
-3.13%
1 Month
-8.82%
6 Months
+13.76%
Year to Date
+37.78%
1 Year
+5.08%
Key Figures
2.550Open
2.550High
77.24KVolume
12.87P/E TTM
52.77P/E Dynamic
--Dividend TTM
0.10%Turnover Ratio
2.550Prev. Close
2.460Low
192.77KTurnover
68.29P/E Static
2.80P/B
0.00%Div Yield TTM
-8.48%ROA
3.19052wk High
49.87Volume Ratio
2.93MNet Profit
80.57MShares
0.1932EPS TTM
-0.02Beta
-14.44%ROE
1.65052wk Low
3.92%Amplitude
60.99%Gross Margin
199.81MMarket Cap
-2.30Reward/Risk
3.44%Risk Rate
Protalix Biotherapeutics Inc's Score
0.00vs previous score
Forecast8.00
Financial Health8.23
Technical3.09
Valuation Dimensions8.01
Institutional Confidence3.00
Risk Assessment5.07
Media Coverage
Coverage Level
Very Low
Very High
Positive
Analyst Rating
Protalix Biotherapeutics Inc Technical Analysis
Technical Indicators
Strong sell
Summary
Sell
Moving Average
Sell
Protalix Biotherapeutics Inc Latest Earnings Call Transcripts
Protalix BioTherapeutics (PLX) Q2 2026 Earnings Call: Elfabrio Drives Revenue Growth
Protalix BioTherapeutics Q2 2026 revenue rose 26.8% to $19.9 million as Elfabrio drove growth, while management reaffirmed its full-year outlook.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
0.05/-0.01
Revenue / Forecast
19.90M/12.93M
Protalix Biotherapeutics Inc Profile
SectorPharmaceuticals
Ticker SymbolPLX
Number of employees207
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| MAK Capital One, LLC | 4.49% |
| BlackRock Institutional Trust Company, N.A. | 4.06% |
| Bashan (Dror) | 3.14% |
| Opaleye Management Inc. | 3.08% |
| Shareholder Types | Proportion |
|---|---|
| Hedge Fund | 9.63% |
| Investment Advisor | 9.41% |
| Investment Advisor/Hedge Fund | 4.05% |
| Individual Investor | 3.88% |
Related Instruments
+0.45%
+0.94%
+0.39%
-3.21%
+1.78%
+0.33%
+1.22%
+1.70%
+0.20%
-0.80%
-1.23%
+0.21%
-0.79%
+0.69%
+0.46%
+0.33%
-0.62%
+0.94%
+0.79%
-0.50%Popular Instruments
52456.000
+123.600 (+0.24%)
29179.700
-121.400 (-0.41%)
7675.600
-1.500 (-0.02%)
13022.000
-18.000 (-0.14%)
63214.000
+435.000 (+0.69%)
6095.600
-0.600 (-0.01%)
100.782
-0.178 (-0.18%)
343.910
-3.815 (-1.10%)
216.000
+5.040 (+2.39%)
4005.190
-11.390 (-0.28%)
FAQs
What is the current price of Protalix Biotherapeutics Inc (PLX)?
The current price of Protalix Biotherapeutics Inc (PLX) is 2.48.
What is the symbol of Protalix Biotherapeutics Inc?
The ticker symbol of Protalix Biotherapeutics Inc is PLX.
What is the 52-week high of Protalix Biotherapeutics Inc?
The 52-week high of Protalix Biotherapeutics Inc is 3.19.
What is the 52-week low of Protalix Biotherapeutics Inc?
The 52-week low of Protalix Biotherapeutics Inc is 1.65.
What is the market capitalization of Protalix Biotherapeutics Inc?
The market capitalization of Protalix Biotherapeutics Inc is 199.81M.
Is Protalix Biotherapeutics Inc (PLX) currently rated as Buy, Hold, or Sell?
According to analysts, Protalix Biotherapeutics Inc (PLX) has an overall rating of Buy, with a price target of 11.00.
What is the Earnings Per Share (EPS TTM) of Protalix Biotherapeutics Inc (PLX)?
The Earnings Per Share (EPS TTM) of Protalix Biotherapeutics Inc (PLX) is 0.19.